Patents Assigned to Shionogi & Co., Ltd.
  • Patent number: 10781210
    Abstract: The present invention provides a compound having TrkA inhibitory activity, or a pharmaceutically acceptable salt thereof. The present invention relates to a compound represented by Formula (I): wherein ?X is ?O or the like, R5 and R5A are hydrogen atoms or the like, —A— is —NR1— or the like, B is substituted or unsubstituted aromatic carbocyclyl or the like, R1 is substituted or unsubstituted alkyl or the like, R2 is a hydrogen atom or the like, —W— is —CH2— or the like, —WA— is —CH2— or the like, R13 is substituted or unsubstituted aromatic carbocyclyl or the like, R14 is substituted or unsubstituted aromatic heterocyclyl or the like, R15 is substituted or unsubstituted alkyl or the like, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same.
    Type: Grant
    Filed: November 15, 2019
    Date of Patent: September 22, 2020
    Assignee: Shionogi & Co., Ltd.
    Inventors: Akira Yukimasa, Kazuya Kano, Kenichiroh Nakamura, Takatsugu Inoue, Motohiro Fujiu
  • Publication number: 20200291025
    Abstract: The present invention provides the compound represented by the following formula (I): wherein a moiety represented by formula: or the like. The symbols are defined in the specification. The compounds of the present invention have MGAT2 inhibitory activity, and are useful as a medicine for treatment of MGAT2-associated diseases including obesity, metabolic syndrome, hyperlipidemia, hypertriglyceridemia, hyper-VLDL-triglyceridemia, hyperfattyacidemia, diabetes mellitus, and arteriosclerosis.
    Type: Application
    Filed: July 13, 2018
    Publication date: September 17, 2020
    Applicant: Shionogi & Co., Ltd.
    Inventors: Kouhei NODU, Yusuke TATENO, Kengo MASUDA, Yuji NISHIURA, Yoshikazu SASAKI, Yu HINATA
  • Patent number: 10774051
    Abstract: A compound represented by Formula (I): wherein or the like Y1 is O or the like; Z1 is C(R4) or N; Z2a is C(R5a) or the like; Z3a is C(R6) or the like; R4, R5a and R6 are each independently a hydrogen atom or the like; R1 is substituted or unsubstituted aromatic carbocyclyl or the like; R2a, R2b, R2c and R2d are each independently a hydrogen atom or the like; X is N(R7a) or the like; R7a is a hydrogen atom or the like; R3 is or the like Ring B is a 6-membered aromatic carbocycle or the like; R9a and R10a are each independently halogen or the like; n is an integer from 1 to 5; m is an integer from 0 to 4; and p1 is an integer from 0 to 3, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: September 15, 2020
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Tomoyuki Ogawa, Hiroyuki Kai, Keiichiro Hirai
  • Publication number: 20200283455
    Abstract: The present invention provides the following compounds having anti-viral activity. A1 is CR1AR1B, S or O; A2 is CR2AR2B, S or O; A3 is CR3AR3B, S or O; A4 is CR4AR4B, S or O; the number of hetero atoms among atoms constituting the ring which consists of A1, A2, A3, A4, nitrogen atom adjacent to A1 and carbon atom adjacent to A1, is 1 or 2; R1A and R1B are each independently hydrogen, halogen, alkyl, or the like; R2A and R2B are each independently hydrogen, halogen, alkyl, or the like; R3A and R3B are each independently hydrogen, halogen, alkyl, or the like; R4A and R4B are each independently hydrogen, halogen, alkyl, or the like; R3A and R3B may be taken together to form non-aromatic carbocycle or non-aromatic heterocycle; X is CH2, S or O; R1 is each independently halogen, hydroxy, or the like; m is any integer of 0 to 2; and n is any integer of 1 to 2.
    Type: Application
    Filed: March 23, 2020
    Publication date: September 10, 2020
    Applicant: Shionogi & Co., Ltd.
    Inventors: Makoto KAWAI, Kenji TOMITA, Toshiyuki AKIYAMA, Azusa OKANO, Masayoshi MIYAGAWA
  • Patent number: 10759814
    Abstract: The present invention provides a pharmaceutical composition containing the following compound having antiviral action: wherein each of the symbols is defined in the specification.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: September 1, 2020
    Assignee: SHIONOGI & CO., LTD.
    Inventor: Makoto Kawai
  • Publication number: 20200261481
    Abstract: A medicament characterized in that (A) a compound represented by the formula (I): its pharmaceutically acceptable salt, or a solvate thereof, wherein P is hydrogen or a group to form a prodrug; A1 is CR1AR1B, S or O; A2 is CR2AR2B, S or O; A3 is CR3AR3B, S or O; A4 is each independently CR4AR4B, S or O; the number of hetero atoms among atoms constituting the ring which consists of A1, A2, A3, A4, nitrogen atom adjacent to A1 and carbon atom adjacent to A4 is 1 or 2; R1A and R1B are each independently hydrogen, halogen, alkyl or the like; R2A and R2B are each independently hydrogen, halogen, alkyl, or the like; R3A and R3B are each independently hydrogen, halogen, alkyl, or the like; R4A are each independently hydrogen, halogen, alkyl, or the like; R4B are each independently hydrogen, halogen, alkyl, or the like; R3A and R3B may be taken together with an adjacent carbon atom to form non-aromatic carbocycle or non-aromatic heterocycle; n is any integer of 1 to 2; and R1 is or the like,
    Type: Application
    Filed: December 14, 2016
    Publication date: August 20, 2020
    Applicant: Shionogi & Co., Ltd.
    Inventors: Takao SHISHIDO, Takeshi NOSHI, Atsuko YAMAMOTO, Mitsutaka KITANO
  • Publication number: 20200262796
    Abstract: A compound represented by Formula (I): Chemical Formula 1 wherein Chemical Formula 2 or the like Y1 is O or the like; Z1 is C(R4) or N; Z2a is C(R5a) or the like; Z3a is C(R6) or the like; R4, R5a and R6 are each independently a hydrogen atom or the like; R1 is substituted or unsubstituted aromatic carbocyclyl or the like; R2a, R2b, R2c and R2d are each independently a hydrogen atom or the like; X is N(R7a) or the like; R7a is a hydrogen atom or the like; R3 is Chemical Formula 3 or the like Ring B is a 6-membered aromatic carbocycle or the like; R9a and R10a are each independently halogen or the like; n is an integer from 1 to 5; m is an integer from 0 to 4; and p is an integer from 0 to 3, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 17, 2020
    Publication date: August 20, 2020
    Applicant: Shionogi & Co., Ltd.
    Inventors: Satoru TANAKA, Tomoyuki OGAWA, Hiroyuki KAI, Yuki OGATA, Keiichiro HIRAI, Noriyuki KUROSE, Yasuhiko FUJII
  • Patent number: 10745491
    Abstract: Provided is a monoclonal antibody or a fragment thereof that selectively inhibits the enzymatic activity of vascular endothelial lipase and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: August 18, 2020
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Shoichi Naito, Junji Onoda, Tasuku Tsukamoto, Katsutoshi Yamada, Shoji Yamane, Yoshito Numata, Kazuhiko Maekawa, Tatsuya Takahashi
  • Publication number: 20200247818
    Abstract: The present invention provides industrially suitable processes for preparing intermediates in the production of substituted polycyclic pyridone derivatives having a cap-dependent endonuclease inhibitory activity. In the process as shown below, wherein each symbol is as defined in the specification, an optically active substituted tricyclic pyridone derivative of the formula (VII) is obtained in high yield and high enantioselectivity by subjecting a compound of the formula (III) or (VI) to intramolecular cyclization with controlling stereochemistry to obtain a compound of the formula (IV) having a removable functional group on an asymmetric carbon, and then removing the functional group thereof.
    Type: Application
    Filed: October 5, 2018
    Publication date: August 6, 2020
    Applicant: Shionogi & Co., Ltd.
    Inventors: Kazuya OKAMOTO, Tatsuhiko UENO, Yoshio HATO, Toshikazu HAKOGI, Shohei MAJIMA
  • Publication number: 20200232973
    Abstract: The disclosure provides a method of measuring an efficacy of a drug composition for cancer and a method for treating a cancer by administering to a subject an effective amount of a pharmaceutical composition having a polypeptide that binds to a peptide produced by cDNA of GenBank ACC No. NM_005201.3 or NM_007720.2.
    Type: Application
    Filed: January 2, 2020
    Publication date: July 23, 2020
    Applicants: Shionogi & Co., Ltd., Osaka University
    Inventors: Tetsuya Yoshida, Yujiro Kidani, Mitsunobu Matsumoto, Takayuki Kanazawa, Satomi Shinonome, Kanji Hojo, Naganari Ohkura, Shimon Sakaguchi, Atsushi Tanaka, Hisashi Wada, Atsunari Kawashima, Norio Nonomura
  • Publication number: 20200222463
    Abstract: The disclosure provides a pharmaceutical composition with a polypeptide that binds to a peptide produced by cDNA of GenBank ACC No. NM_005201.3 or NM_007720.2, and methods of use thereof.
    Type: Application
    Filed: January 2, 2020
    Publication date: July 16, 2020
    Applicants: Shionogi & Co., Ltd., Osaka University
    Inventors: Tetsuya Yoshida, Yujiro Kidani, Mitsunobu Matsumoto, Takayuki Kanazawa, Satomi Shinonome, Kanji Hojo, Naganari Ohkura, Shimon Sakaguchi, Atsushi Tanaka, Hisashi Wada, Atsunari Kawashima, Norio Nonomura
  • Patent number: 10696707
    Abstract: The present invention is the following Amphotericin B derivative: wherein each symbol is defined in description. The compound of the present invention has 16th position (X) is urea structure, cyclic structure, hydroxyalkyl or substituted monoalkylcarbamoyl. The compound of the present invention has antifungal activity.
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: June 30, 2020
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Keisuke Miyazaki, Kenji Takaya, Takafumi Ohara, Hideki Sugimoto, Manabu Fujitani, Yuki Ogata, Naoyuki Suzuki
  • Publication number: 20200147074
    Abstract: The present invention offers the manufacturing method of the solid formulation wherein the standard deviation of the active ingredient content in the solid formulation becomes 5% or less by mixing the excipients which have a median particle size of 15 or more times, preferably 20 times or more to the median particle size of an active ingredient.
    Type: Application
    Filed: December 26, 2017
    Publication date: May 14, 2020
    Applicant: Shionogi & Co., Ltd.
    Inventors: Akira MASHIMO, Shunji ICHIO
  • Patent number: 10640495
    Abstract: The present invention provides a compound having a TrkA inhibitory activity or a pharmaceutically acceptable salt thereof. The present invention relates to a compound represented by Formula (I): wherein -L- is —C(?X)—, or the like, —Z— is —NR5—, or the like, —ZA— is —NR5A—, or the like, B is substituted or unsubstituted aromatic carbocyclyl, or the like, Y is a single bond, or the like, the ring C is a substituted or unsubstituted aromatic heterocycle, or the like, R2 is a hydrogen atom, or the like, and the group represented by is a group represented by Formula: or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same.
    Type: Grant
    Filed: July 6, 2016
    Date of Patent: May 5, 2020
    Assignee: Shionogi & Co., Ltd.
    Inventors: Akira Yukimasa, Kenichiroh Nakamura, Masanao Inagaki, Kazuya Kano, Motohiro Fujiu, Hiroki Yamaguchi, Kayoko Hata, Takatsugu Inoue
  • Patent number: 10633397
    Abstract: The present invention provides the following compounds having anti-viral activity. A1 is CR1AR1B, S or O; A2 is CR2AR2B, S or O; A3 is CR3AR3B, S or O; A4 is CR4AR4B, S or O; the number of hetero atoms among atoms constituting the ring which consists of A1, A2, A3, A4, nitrogen atom adjacent to A1 and carbon atom adjacent to A1, is 1 or 2; R1A and R1B are each independently hydrogen, halogen, alkyl, or the like; R2A and R2B are each independently hydrogen, halogen, alkyl, or the like; R3A and R3B are each independently hydrogen, halogen, alkyl, or the like; R4A and R4B are each independently hydrogen, halogen, alkyl, or the like; R3A and R3B may be taken together to form non-aromatic carbocycle or non-aromatic heterocycle; X is CH2, S or O; R1 is each independently halogen, hydroxy, or the like; m is any integer of 0 to 2; and n is any integer of 1 to 2.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: April 28, 2020
    Assignee: SHIONOGI & CO., LTD.
    Inventor: Makoto Kawai
  • Publication number: 20200109433
    Abstract: The present invention is related to a method for evaluation of drug efficacy of a medicine having a therapeutic or preventive effect against a disease related to EL activity wherein phosphatidylinositol or lysophosphatidylinositol is used as an indicator. The present invention is also related to a method for screening an inhibitor of EL activity using phosphatidylinositol and a kit for use in the method.
    Type: Application
    Filed: December 6, 2019
    Publication date: April 9, 2020
    Applicant: SHIONOGI & CO., LTD.
    Inventors: Takashi ONO, Atsuko YAMAMOTO, Shuhei SHIGAKI
  • Publication number: 20200071424
    Abstract: Provided is a humanized monoclonal antibody or an antibody fragment thereof that selectively inhibits the enzymatic activity of vascular endothelial lipase and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.
    Type: Application
    Filed: November 18, 2019
    Publication date: March 5, 2020
    Applicant: Shionogi & Co., Ltd.
    Inventors: Shoichi NAITO, Hiroaki AINO, Etsuo NAKAMURA, Sunao IMAI, Shoji YAMANE
  • Patent number: 10570215
    Abstract: Provided is a humanized monoclonal antibody or an antibody fragment thereof that selectively inhibits the enzymatic activity of vascular endothelial lipase and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: February 25, 2020
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Shoichi Naito, Hiroaki Aino, Etsuo Nakamura, Sunao Imai, Shoji Yamane
  • Publication number: 20200055873
    Abstract: The present invention provides a novel compound having antiviral activity, especially HIV replication inhibitory activity and a medicament containing the same. The compound represented by the formula: wherein A3 is CR3A, CR3AR3B, N or NR3C; R3A, R3B, R4A and R4B are each independently a hydrogen atom, halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkynyl, or substituted or unsubstituted non-aromatic carbocyclyl; R3C is a hydrogen atom, substituted or unsubstituted alkyl, or substituted or unsubstituted non-aromatic carbocyclyl; ring T1 is substituted or unsubstituted nitrogen-containing non-aromatic heterocycle; R1 is a hydrogen atom, halogen, cyano, or substituted or unsubstituted alkyl; R2 is each independently substituted or unsubstituted alkyl or the like: n is 1 or 2; R3 is substituted or unsubstituted aromatic carbocyclyl or the like; R4 is a hydrogen atom or a carboxy protecting group.
    Type: Application
    Filed: October 28, 2019
    Publication date: February 20, 2020
    Applicant: Shionogi & Co., Ltd.
    Inventors: Yoshinori Tamura, Shuichi Sugiyama, Akira Matsumura, Toshiyuki Akiyama, Yutaka Tomida
  • Publication number: 20200048257
    Abstract: Provided are a novel compound having an antagonistic activity for the P2X7 receptor, and a pharmaceutical composition having an antagonistic activity for the P2X7 receptor. The compound represented by Formula (I): wherein the symbols are defined in the specification, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 16, 2017
    Publication date: February 13, 2020
    Applicant: Shionogi & Co., Ltd.
    Inventors: Koji MASUDA, Shuichi SUGIYAMA, Toru YAMADA, Eiichi KOJIMA, Tomoyuki OGAWA, Naotake KOBAYASHI, Hiroyuki KAI